イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

astrazeneca s.p.a. - formoterolo e budesonide - formoterolo e budesonide

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

astrazeneca s.p.a. - formoterolo e budesonide - formoterolo e budesonide

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

simesa s.p.a. - formoterolo e budesonide - formoterolo e budesonide

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

pharmaxis europe limited - altri diagnostici - altri diagnostici

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - formoterolo e budesonide - formoterolo e budesonide

イタリア - イタリア語 - Ministero della Salute

flaem nuova spa - apparecchiature per aerosol

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

astrazeneca s.p.a. - formoterolo - formoterolo

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

epifarma s.r.l - ambroxolo - ambroxolo

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

almus s.r.l. - ambroxolo - ambroxolo

欧州連合 - イタリア語 - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).